Literature DB >> 9444794

Vascular endothelial growth factor: a key mediator of neoangiogenesis. A review.

A Amoroso1, F Del Porto, C Di Monaco, P Manfredini, A Afeltra.   

Abstract

Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that exerts in vivo a key role in physiological and pathological neoangiogenesis by stimulating endothelial cell proliferation and vessel hyperpermeability. VEGF exists as one of four different isoforms, respectively, VEGF 121, VEGF 165, VEGF 189, VEGF 206, and seems to be a crucial mediator of physiological neoangiogenesis during the embryonic development and the female cycle. VEGF also has a major role in the pathogenesis of many diseases including hypervascularized tumors, rheumatoid arthritis, cutaneous diseases and proliferative retinopathies. Anti-VEGF anti-bodies or VEGF agonists may represent a novel approach in the treatment of these diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444794

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

1.  Creation of bony microenvironment with CaP and cell-derived ECM to enhance human bone-marrow MSC behavior and delivery of BMP-2.

Authors:  Yunqing Kang; Sungwoo Kim; Ali Khademhosseini; Yunzhi Yang
Journal:  Biomaterials       Date:  2011-05-31       Impact factor: 12.479

Review 2.  Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.

Authors:  V F Azevedo; R Pecoits-Filho
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

3.  Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade.

Authors:  Alan Jackson; Andrea Kassner; Deborah Annesley-Williams; Helen Reid; Xiau-Ping Zhu; Kah-Loh Li
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

4.  Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging.

Authors:  Bei Ding; Hua Wei Ling; Ke Min Chen; Hong Jiang; Yan Bo Zhu
Journal:  Neuroradiology       Date:  2006-08-26       Impact factor: 2.804

5.  Serum VEGF and b-FGF profiles after tension-free or conventional hernioplasty.

Authors:  Gaetano Di Vita; Rosalia Patti; Pietro D'Agostino; Francesco Arcoleo; Giuseppe Caruso; Matteo Arcara; Valentina Davì; Enrico Cillari
Journal:  Langenbecks Arch Surg       Date:  2005-09-23       Impact factor: 3.445

6.  Comparison between CT and MR in perfusion imaging assessment of high-grade gliomas.

Authors:  M De Simone; C F Muccio; S M Pagnotta; G Esposito; A Cianfoni
Journal:  Radiol Med       Date:  2012-03-19       Impact factor: 3.469

7.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.

Authors:  Janine M Lupo; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

8.  Mass spectrometry identification of potential mediators of progestin-only contraceptive-induced abnormal uterine bleeding in human endometrial stromal cells.

Authors:  John P Shapiro; Murat Basar; Umit A Kayisli; Ozlem Guzeloglu-Kayisli; S Joseph Huang; Adrian A Suarez; Hatice Gulcin Ozer; Frederick Schatz; Charles J Lockwood
Journal:  Contraception       Date:  2014-11-21       Impact factor: 3.375

9.  Investigating tumor perfusion by hyperpolarized 13 C MRI with comparison to conventional gadolinium contrast-enhanced MRI and pathology in orthotopic human GBM xenografts.

Authors:  Ilwoo Park; Cornelius von Morze; Janine M Lupo; Jan H Ardenkjaer-Larsen; Achuta Kadambi; Daniel B Vigneron; Sarah J Nelson
Journal:  Magn Reson Med       Date:  2016-02-19       Impact factor: 4.668

10.  Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.

Authors:  Janine M Lupo; Emma Essock-Burns; Annette M Molinaro; Soonmee Cha; Susan M Chang; Nicholas Butowski; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.